Disc Medicine, Inc. (NASDAQ:IRON – Get Free Report) has been assigned an average recommendation of “Buy” from the ten analysts that are presently covering the firm, Marketbeat reports. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $53.78.
A number of equities research analysts have recently weighed in on the company. BMO Capital Markets boosted their price target on Disc Medicine from $40.00 to $70.00 in a research note on Monday, June 12th. Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $50.00 to $75.00 in a research report on Friday, June 9th. HC Wainwright lifted their price target on Disc Medicine from $66.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Cantor Fitzgerald increased their price objective on Disc Medicine from $45.00 to $65.00 in a report on Friday, June 9th. Finally, Stifel Nicolaus lifted their target price on Disc Medicine from $50.00 to $65.00 in a report on Friday, June 23rd.
Insider Activity at Disc Medicine
Hedge Funds Weigh In On Disc Medicine
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IRON. Ameritas Investment Partners Inc. acquired a new position in shares of Disc Medicine during the 2nd quarter worth about $28,000. Bank of America Corp DE increased its stake in Disc Medicine by 134,000.0% during the 1st quarter. Bank of America Corp DE now owns 2,682 shares of the company’s stock worth $57,000 after buying an additional 2,680 shares in the last quarter. Citigroup Inc. acquired a new position in shares of Disc Medicine during the fourth quarter valued at approximately $101,000. California State Teachers Retirement System purchased a new position in shares of Disc Medicine in the second quarter valued at approximately $114,000. Finally, Barclays PLC boosted its stake in shares of Disc Medicine by 2,709.5% in the first quarter. Barclays PLC now owns 5,619 shares of the company’s stock worth $119,000 after acquiring an additional 5,419 shares during the last quarter.
Disc Medicine Price Performance
NASDAQ IRON opened at $48.91 on Friday. Disc Medicine has a one year low of $11.80 and a one year high of $57.70. The company’s 50-day simple moving average is $51.05 and its two-hundred day simple moving average is $39.96.
Disc Medicine (NASDAQ:IRON – Get Free Report) last issued its quarterly earnings data on Friday, August 11th. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.12. Analysts predict that Disc Medicine will post -3.47 earnings per share for the current year.
About Disc Medicine
Disc Medicine, Inc, together with its subsidiaries, operates as a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
- Five stocks we like better than Disc Medicine
- How to Invest in Music Stocks
- 3 Reasons This Sleeping Giant Is About To Wake Up
- How to Invest in Pharmaceutical Companies
- MarketBeat Week in Review – 9/18 – 9/22
- Pros And Cons Of Monthly Dividend Stocks
- 52-week Low Names To Tip The Upside Scale In Your Favor
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.